Molecular genetic tumor markers in non-small cell lung cancer

Anticancer Research

Volumn 25, Issue 2 B, 2005, Pages 1193-1196

  Oyama, Tsunehiro ^a   Osaki, Toshihiro ^a   Baba, Tetsuro ^a   Nagata, Yoshika ^a   Mizukami, Makiko ^a   So, Tetsuya ^a   Nakata, Shoji ^a   Ichiki, Yoshinobu ^a   Uramoto, Hidetaka ^a   Sugaya, Masakazu ^a   Yoshimatsu, Takashi ^a   Morita, Masaru ^a   Hanagiri, Takeshi ^a   Sugio, Kenji ^a   Kawamoto, Toshihiro ^a   Yasumoto, Kosei ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Molecular genetic tumor marker; Non small cell lung cancer; Review

Indexed keywords

BETA CATENIN; CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYCLOOXYGENASE 2; CYTOCHROME P450 1A1; CYTOCHROME P450 2A6; CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUCURONOSYLTRANSFERASE 1A1; GLUTATHIONE TRANSFERASE; GLUTATHIONE TRANSFERASE M1; GLUTATHIONE TRANSFERASE P1; GROWTH FACTOR; MATRIX METALLOPROTEINASE; PROTEIN P16; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN; TELOMERASE; TUMOR MARKER; UNCLASSIFIED DRUG; UVOMORULIN; VASCULOTROPIN;

CANCER INCIDENCE; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER THERAPY; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENOMICS; HUMAN; JAPAN; LUNG NON SMALL CELL CANCER; METASTASIS; MOLECULAR GENETICS; ONCOGENE C KIT; ONCOGENE K RAS; ONCOGENE MYC; ONCOGENE NEU; PRIORITY JOURNAL; PROTEOMICS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL CARCINOMA;

CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION PROFILING; GENE TARGETING; GENES, TUMOR SUPPRESSOR; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; NEOPLASM METASTASIS; ONCOGENES; TUMOR MARKERS, BIOLOGICAL;

EID: 20244378550     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Gaspar MJ, Diez M, Rodriguez A, Ratia T, Martin Duce A, Galvan M, Granell J and Coca C: Clinical value of CEA and CA125 regarding relapse and metastasis in resectable non-small cell lung cancer. Anticancer Res 23: 3427-3432, 2003.
2. Trape J, Buxo J, Perez de Olaguer J and Vidal C: Tumor markers as prognostic factors in treated non-small cell lung cancer. Anticancer Res 23: 4277-4281, 2003.
3. Nieder C, Andratschke N, Jeremic B and Molls M: Comparison of serum growth factors and tumor markers as prognostic factors for survival in non-small cell lung cancer. Anticancer Res 23: 5117-5123, 2003.
4. Schneider J, Philipp M, Velcovsky HG, Morr H and Katz N: Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA) and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases. Anticancer Res 23: 885-893, 2003.
5. Muley T, Dienemann H and Ebert W: CYFRA 21-1 and CEA are independent prognostic factors in 153 operated stage I NSCLC patients. Anticancer Res 24: 1953-1956, 2004.
6. Gu CD, Oyama T, Osaki T, Li J, Takenoyama M, Izumi H, Sugio K, Kohno K and Yasumoto K: Low expression of polypeptide GalNAc N-acetylgalactosaminyl transferase-3 in lung adenocarcinoma: impact on poor prognosis and early recurrence. Br J Cancer 90: 436-442, 2004.
7. Osaki T, Oyama T, Inoue M, Gu CD, Kodate M, Aikawa M, So T, Mizukami M, Mitsudomi T and Yasumoto K: Molecular biological markers and micrometastasis in resected non-small-cell lung cancer. Prognostic implications. Jpn J Thorac Cardiovasc Surg 49: 545-551, 2001.
8. Osaki T, Oyama T, Gu CD, Yamashita T, So T, Takenoyama M, Sugio K and Yasumoto K: Prognostic impact of micrometastatic tumor cells in the lymph nodes and bone marrow of patients with completely resected stage I non-small-cell lung cancer. J Clin Oncol 20: 2930-2936, 2002.
9. Mitsudomi T and Takahashi T: Genetic alteration of lung cancer as a prognostic marker and its therapeutic implications. Gan To Kagaku Ryoho 24(Suppl): 345-352, 1997.
10. Mitsudomi T and Oyama T: Molecular diagnosis in lung cancer. Nippon Rinsho 60(Suppl): 233-237, 2002.
11. Oyama T, Matsumoto A, Isse T, Kim Y-D, Ozaki S, Osaki T, Sugio K, Yasumoto K and Kawamoto T: Evidence-based prevention (EBP): approach to lung cancer prevention based on cytochrome 1A1 and cytochrome 2E1 polymorphism. Anticancer Res 23: 1731-1737, 2003.
12. Ingelman-Sundberg M: Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes. Mutat Res 482: 11-19, 2001.
13. Oyama T, Kawamoto T, Matsumoto A, Isse T, Ozaki S and Yasumoto K: Evidence based prevention (EBP): evidence-based approach to prevention of lung cancer by application of cytochrome 2E1 polymorphism. J UOEH 24: 413-421, 2002.
14. Oyama T, Mitsudomi T, Kawamoto T, Ogami A, Osaki T, Kodama Y and Yasumoto K: Detection of CYP1A1 gene polymorphism using designed RFLP and distributions of CYP1A1 genotypes in Japanese. Int Arch Occup Environ Health 67: 253-256, 1995.
15. Oyama T, Kawamoto T, Mizoue T, Nishida K, Osaki T, Sugio K, Yasumoto K and Mitsudomi T: p53 mutations of lung cancer are not significantly affected by CYP1A1 or GSTM1 polymorphisms. Int J Oncol 11: 305-309, 1997.
16. Oyama T, Kawamoto T, Mizoue T, Yasumoto K, Kodama Y and Mitsudomi T: N-acetylation polymorphism in patients with lung cancer and its association with p53 gene mutation. Anticancer Res 17: 577-581, 1997.
17. Oyama T, Kawamoto T, Mizoue T, Sugio K, Kodama Y, Mitsudomi T and Yasumoto K: Cytochrome P450 2E1 polymorphism as a risk factor for lung cancer: in relation to p53 gene mutation. Anticancer Res 17: 583-587, 1997.
18. Ruano-Ravina A, Figueiras A, Loidi L and Barros-Dios JM: GSTM1 and GSTT1 polymorphisms, tobacco and risk of lung cancer: a case-control study from Galicia, Spain. Anticancer Res 23: 4333-4337, 2003.
19. Gu CD, Osaki T, Oyama T, Inoue M, Kodate M, Dobashi K, Oka T and Yasumoto K: Detection of micrometastatic tumor cells in pNO lymph nodes of patients with completely resected non-small cell lung cancer: impact on recurrence and survival. Ann Surg 235: 133-139, 2002.
20. Coello MC, Luketich JD, Litle VR and Godfrey TE: Prognostic significance of micrometastasis in non-small-cell lung cancer. Clin Lung Cancer 5: 214-225, 2004.
21. Field RW, Smith BJ, Platz CE, Robinson RA, Neuberger JS, Brus CP and Lynch CF: Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review. J Natl Cancer Inst 96: 1105-1107, 2004.
22. Oyama T, Osaki T, Nose N, Ichiki Y, Inoue M, Imoto H, Yoshimatsu T, Kodate M, Uramoto H, Mizoue T, Yano K and Yasumoto K: Evaluations of p53 immunoreactivity, nucleolar organizer regions, and proliferating cell nuclear antigen in non-small cell lung carcinoma. Anticancer Res 20: 505-510, 2000.
23. Jumper C, Cobos E and Lox C: The circulating urokinase plasminogen activator (uPA) and its soluble receptor (suPAR) are not up-regulated by the circulating P105 fraction of the HER-2/neu proto-oncogene: in vivo evidence from patients with advanced non-small cell lung cancer (NSCLC). Anticancer Res 22: 2073-2076, 2002.
24. Shibata Y, Hidaka S, Tagawa Y and Nagayasu T: Bcl-2 protein expression correlates with better prognosis in patients with advanced non-small cell lung cancer. Anticancer Res 24: 1925-1928, 2004.
25. Kalogeraki A, Bouros D, Zoras O, Karabekios S, Chalkiadakis G, Stathopoulos E, Siafakas N and Delides GS: E-cadherin expression on fine-needle aspiration biopsies in primary lung adenocarcinomas is related to tumor differentiation and invasion. Anticancer Res 23: 3367-3371, 2003.
26. Volm M, Koomagi R, Efferth T and Mattern J: Protein expression profiles of non-small cell lung carcinomas: correlation with histological subtype. Anticancer Res 22: 2321-2324, 2002.
27. Bergqvist M, Brattstrom D, Gullbo J, Hesselius P, Brodin O and Wagenius G: p53 status and its in vitro relationship to radiosensitivity and chemosensitivity in lung cancer. Anticancer Res 23: 1207-1212, 2003.
28. Ross JS, Schenkein DP, Kashala O, Linette GP, Stec J, Symmans WF, Pusztai L and Hortobagyi GN: Pharmacogenomics. Adv Anat Pathol 11: 211-220, 2004.
29. Oyama T, Kagawa N, Kunugita N, Kitagawa K, Ogawa M, Yamaguchi T, Suzuki R, Kinaga T, Yashima Y, Ozaki S, Isse T, Kim Y-D, Kim H and Kawamoto T: Expression of cytochrome P450 in tumor tissues and its association with cancer development. Front Biosci 9: 1967-1976, 2004.
30. Borthakur G and Cortes JE: Imatinib mesylate in the treatment of chronic myelogenous leukemia. Int J Hematol 79: 411-419, 2004.
31. Joensuu H and Kindblom LG: Gastrointestinal stromal tumors - a review. Acta Orthop Scand 75(Suppl): 62-71, 2004.
32. Mechtersheimer G, Egerer G, Hensel M, Rieker RJ, Libicher M, Lehnert T and Penzel R: Gastrointestinal stromal tumours and their response to treatment with the tyrosine kinase inhibitor imatinib. Virchows Arch 444: 108-118, 2004.
33. Leyland-Jones B: Trastuzumab: hopes and realities. Lancet Oncol 3: 137-144, 2002.
34. Nabholtz JM, Reese DM, Lindsay MA and Riva A: HER2-positive breast cancer: update on Breast Cancer International Research Group trials. Clin Breast Cancer 3(Suppl 2): s75-s79, 2002.
35. Mendelsohn J and Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21: 2787-2799, 2003.
36. Minna JD, Gazdar AF, Sprang SR and Herz J: A bull's eye for targeted lung cancer therapy. Science 304: 1458-1461, 2004.
37. Gridelli C, Rossi A, Maione P, Guerriero C, Airoma G, Colantuoni G and Barzelloni ML: Gefitinib as salvage therapy in pretreated patients with advanced non-small cell lung cancer. Data from a compassionate use program. Anticancer Res 24: 1873-1877, 2004.
38. Kozuki T, Kiura K, Ueoka H, Tabata M, Date H, Hamazaki S, Bessho A and Tanimoto M: Long-term effect of gefitinib (ZD1839) on squamous cell carcinoma of the lung. Anticancer Res 24: 393-396, 2004.
39. Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn WDJ, Morse D, Abraham S, Rahman A, Liang C, Lostritto R, Baird A and Pazdur R: United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 10: 1212-1218, 2004.
40. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, Naoki K, Sasaki H, Fujii Y, Eck MJ, Sellers WR, Johnson BE and Meyerson M: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004.
41. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J and Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004.
42. Stratton MR and Futreal PA: Cancer: understanding the target. Nature 430: 30, 2004.
43. Sandler AB, Johnson DH and Herbst RS: Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer. Clin Cancer Res 10(12 pt 2): 4258s-4262s, 2004.
44. Sridhar SS and Shepherd FA: Targeting angiogenesis: a review of angiogenesis inhibitors in the treatment of lung cancer. Lung Cancer 4(suppl 1): s81-s91, 2003.
45. Grant GM, Fortney A, Gorreta F, Estep M, Del Giacco L, Van Meter A, Christensen A, Appalla L, Naouar C, Jamison C, Al-Timimi A, Donovan J, Cooper J, Garrett C and Chandhoke V: Microarrays in cancer research. Anticancer Res 24: 441-448, 2004.
46. Garber ME, Troyanskaya OG, Schluens K, Petersen S, Thaesler Z, Pacyna-Gengelbach M, van de Rijn M, Rosen GD, Perou CM, Whyte RI, Altman RB, Brown PO, Botstein D and Petersen I: Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci USA 98: 13784-13789, 2001.
47. Bhattacharjee A, Richards WG, Staunton J, Li C, Monti S, Vasa P, Ladd C, Beheshti J, Bueno R, Gillette M, Loda M, Weber G, Mark EJ, Lander ES, Wong W, Johnson BE, Golub TR, Sugarbaker DJ and Meyerson M: Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci USA 98: 13790-13795, 2001.
48. de Lange R, Dimoudis N and Weidle UH: Identification of genes associated with enhanced metastasis of a large cell lung carcinoma cell line. Anticancer Res 23: 187-194, 2003.
49. Nakamura H, Saji H, Ogata A, Hosaka M, Hagiwara M, Saijo T, Kawasaki N and Kato H: cDNA microarray analysis of gene expression in pathologic Stage IA non-small cell lung carcinomas. Cancer 97: 2798-2805, 2003.
50. Sun Z, Fu X, Zhang L, Yang X, Liu F and Hu G: A protein chip system for parallel analysis of multi-tumor markers and its application in cancer detection. Anticancer Res 24: 1159-1165, 2004.